Last reviewed · How we verify
octreotide capsules
octreotide capsules is a somatostatin analog Small molecule drug developed by Chiasma, Inc.. It is currently in Phase 3 development for Acromegaly, Gastrointestinal carcinoid syndrome, Hormone-secreting tumors. Also known as: MYCAPSSA, Injection SRLs, MYCAPSSA™, Formerly known as Octreolin™.
Octreotide capsules mimic the natural hormone somatostatin to decrease production of growth hormone and other hormones.
Octreotide capsules mimic the natural hormone somatostatin to decrease production of growth hormone and other hormones. Used for Acromegaly, Gastrointestinal carcinoid syndrome, Hormone-secreting tumors.
At a glance
| Generic name | octreotide capsules |
|---|---|
| Also known as | MYCAPSSA, Injection SRLs, MYCAPSSA™, Formerly known as Octreolin™ |
| Sponsor | Chiasma, Inc. |
| Drug class | somatostatin analog |
| Target | somatostatin receptor |
| Modality | Small molecule |
| Therapeutic area | Endocrinology |
| Phase | Phase 3 |
Mechanism of action
By binding to somatostatin receptors on the surface of cells, octreotide reduces the secretion of growth hormone and other hormones, such as insulin and gastrin. This can help to control symptoms associated with acromegaly and other conditions.
Approved indications
- Acromegaly
- Gastrointestinal carcinoid syndrome
- Hormone-secreting tumors
Common side effects
- Diarrhea
- Nausea
- Abdominal pain
- Headache
- Injection site reaction
Key clinical trials
- A Study to Evaluate the Safety and Efficacy of Paltusotine for the Treatment of Acromegaly (ACROBAT Evolve) (PHASE2)
- Comparison of Oral Octreotide Capsules to Injectable Somatostatin Analogs in Acromegaly (PHASE3)
- Efficacy and Safety of Octreotide Capsules (MYCAPSSA) in Acromegaly (PHASE3)
- A First-in-Human Study of the RaniPill, an Oral Drug Delivery Platform (PHASE1)
- Study of Telotristat Etiprate (LX1606) in Participants With Symptomatic Carcinoid Syndrome Not Managed by Stable-Dose Octreotide Therapy (PHASE2)
- Efficacy and Safety of Octreotide (MYCAPSSA™ [Formerly Octreolin™]) for Acromegaly (PHASE3)
- 90Y DOTA/Retinoic Acid for Neuroblastoma and Neuroendocrine Tumor (NET) (PHASE2)
- Gastrointestinal Motility in Patients With Neuroendocrine Tumors
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- octreotide capsules CI brief — competitive landscape report
- octreotide capsules updates RSS · CI watch RSS
- Chiasma, Inc. portfolio CI
Frequently asked questions about octreotide capsules
What is octreotide capsules?
How does octreotide capsules work?
What is octreotide capsules used for?
Who makes octreotide capsules?
Is octreotide capsules also known as anything else?
What drug class is octreotide capsules in?
What development phase is octreotide capsules in?
What are the side effects of octreotide capsules?
What does octreotide capsules target?
Related
- Drug class: All somatostatin analog drugs
- Target: All drugs targeting somatostatin receptor
- Manufacturer: Chiasma, Inc. — full pipeline
- Therapeutic area: All drugs in Endocrinology
- Indication: Drugs for Acromegaly
- Indication: Drugs for Gastrointestinal carcinoid syndrome
- Indication: Drugs for Hormone-secreting tumors
- Also known as: MYCAPSSA, Injection SRLs, MYCAPSSA™, Formerly known as Octreolin™
- Compare: octreotide capsules vs similar drugs
- Pricing: octreotide capsules cost, discount & access